The publications presented on this site may contain investigational and exploratory scientific information about HYLENEX® recombinant (hyaluronidase human injection), ENHANZE® Drug Delivery Technology and other products related to co-formulation. No conclusions of safety or efficacy should be drawn in the absence of or prior to FDA approval.

ENHANZE® Drug Delivery Technology

Date Title
Locke, K., et al. ENHANZE® Drug Delivery Technology: A Novel Approach to Subcutaneous Administration Using Recombinant Human Hyaluronidase PH20; Drug Delivery; 2019 02/11/19
Kang D., et al. Porcine Model to Evaluation Local Tissue Tolerability Associated with Subcutaneous Delivery of Protein; Journal of Pharmacological and Toxicological Methods; 2013 05/01/13
Kang D., et al. Recombinant Human Hyaluronidase PH20 (rHuPH20) Facilitates Subcutaneous Infusions of Large Volumes of Immunoglobulin in a Swine Model; Drug Delivery and Translational Research; 2012 04/27/12
Bookbinder, L.H., et al. A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics; Journal of Controlled Release; 2006 08/28/06

Other

Date Title
Bano F., et al. Single-Molecule Unbinding Forces between the Polysaccharide Hyaluronan and its Binding Proteins; Biophysical Journal; 2018 06/19/18

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

February 24, 2021 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
February 23, 2021 Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
February 23, 2021 Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
Copyright© 2015-2019. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.55.0.1

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok